The Dangers Beyond Psychedelics
For decades, psychedelics have been depicted as dangerous and unpredictable, leading to widespread public fear and misunderstanding. Despite evidence that millions of American adults have engaged in legal hallucinogen use over the past year, the narrative surrounding psychedelics remains heavily influenced by outdated perceptions that solely emphasize their risk and potential for abuse, rather than fostering an objective understanding of their nature.
Recent clinical trials from renowned institutions like Johns Hopkins and Multidisciplinary Association for Psychedelic Studies (MAPS) have investigated the therapeutic potential of psychedelics. Albert Garcia-Romeu, PhD, the associate director of the Center for Psychedelic and Consciousness Research at Johns Hopkins University, said that “psychedelics have been illegal for years, and in the next several years there will likely be a significant shift because some of these drugs will be classified as medicine.” As mental illness - including conditions such as depression, anxiety, and PTSD - continues to affect an increasing number of people, many are turning to these substances as a promising alternative to traditional treatments.
With the growing demand for psychedelic treatments, pharmaceutical startups and investors seek to develop proprietary drugs. Tech entrepreneurs and venture capitalists are bolstering this growth, betting on the future of psychedelics. Among them, billionaire Peter Thiel, best known for co-founding PayPal, has invested heavily in Atai Life Sciences, a biotechnology company focused on developing psychedelic-based treatments. Their financial resources can accelerate innovation in mental health treatments while ensuring standardization and quality control for safety and efficacy. This shift toward commercialization not only expands access to treatments but also stimulates economic growth and job creation. However, this rapid expansion also raises questions about the ethical and regulatory challenges of bringing psychedelics into mainstream medicine. As commercialization accelerates, specifically economic worries and fear heighten.
There are many concerns that come with large companies controlling the psychedelic market. Their increasing presence has raised fear because the possibility of companies monopolizing the market becomes increasingly prevalent. For instance, a study in the Harvard Law Review Forum underscored that the current patent framework might inadvertently favor large pharmaceutical companies over smaller innovators, explicitly saying how “patents are a form of government-granted monopoly.” It acts as a barrier to entry and eliminates competition in the market. Newer startups and research facilities are the ones to suffer because they face costly licensing fees and legal barriers. This potentially slows down the pace of overall developments in psychedelic medicine because companies with patents have no need to improve their product with no competition. Similarly, British pharmaceutical company Compass Pathways has been aggressively claiming patents for psilocybin formulations which gives them exclusive rights to developing certain types of psychedelics. This hoarding tactic of patents has led to questions about whether these patents represent genuine therapeutic innovation or simply an attempt at monopoly market exclusivity. These companies who focus on the control of intellectual property can threateningly build a system wherein only they are benefiting rather than attempting to build a free market.
Although commercializing healthcare presents many economic concerns, there are viable compromises that can balance corporate interests with public benefit. One potential solution is to establish a regulatory framework that allows large pharmaceutical companies to invest in psychedelic research while adhering to ethical and equitable practices. Such a framework would prioritize innovation, protect traditional knowledge, and ensure broad access to treatments - essentially placing tighter oversight on companies’ power. For instance, companies could adopt "patent pledges", which are commitments to limit the enforcement of patents. This would limit aggressive enforcement of patents on naturally occurring compounds or minor chemical modifications. This approach would prevent proprietary claims from restricting broader research efforts, particularly in cases where people have long used these substances in traditional medicine. Patent pledges have been successfully implemented in other industries - as shown through Tesla’s open source patent pledge - and could serve as a model for ensuring that psychedelic-based treatments remain accessible.
Additionally, pharmaceutical firms could agree to implement tiered intellectual property rights that favor smaller companies, research institutions, or non-profit organizations. The tiered system provides different levels of exclusivity for different companies based on factors like social impact and novelty which could help prevent market monopolization while still incentivizing large companies to invest in research and development. By offering a structured yet flexible approach, these measures would create a more inclusive landscape where both corporate entities and independent researchers can contribute to advancing psychedelic medicine.
The means for psychedelic advancement must be regarded with intense scrutiny to prevent overexploitation that can lead to the destruction of the market entirely. If companies prioritize profit over responsible development, they risk inflating prices, limiting accessibility, and stifling independent research. Without balanced regulations, the commercialization of psychedelics could backfire, reinforcing skepticism and hindering their integration into mainstream medicine. Sustainable growth, transparency, and equitable access must guide the industry's evolution to ensure these treatments reach those who need them most.
Works Cited
“Bifurcation Squared: Compass Lobbies for Narrow Rescheduling in Colorado, Virginia; Pushes Back on State Policy Reforms.” Psychedelic Alpha, January 23, 2025. https://psychedelicalpha.com/news/bifurcation-squared-compass-lobbies-for-narrow-rescheduling-in-colorado-virginia-pushes-back-on-state-policy-reforms#:~:text=In%202020%2C%20Compass%20Pathways%20co,such%20initiative%20in%20the%20U.S.
Kary, Tiffany. “Meet the Derivatives Mastermind Now Funding ’Shrooms Science.” Bloomgberg, August 29, 2022. https://www.bloomberg.com/news/newsletters/2022-08-29/nyu-magic-mushrooms-research-funded-by-investor-carey-turnbull.
Mason Marks I. Glenn Cohen, Mason Marks, and I. Glenn Cohen. “Patents on Psychedelics: The Next Legal Battlefront of Drug Development.” Harvard Law Review, March 24, 2023. https://harvardlawreview.org/forum/no-volume/patents-on-psychedelics-the-next-legal-battlefront-of-drug-development/.
Shead, Sam. “Peter Thiel Backs Berlin Start-up Making Psychedelics in $125 Million Round.” CNBC, November 23, 2020. https://www.cnbc.com/2020/11/23/peter-thiel-backs-psychedelics-startup-atai.html.
Siegel, Joshua S, James E Daily, Demetrius A Perry, and Ginger E Nicol. “Psychedelic Drug Legislative Reform and Legalization in the US.” JAMA psychiatry, January 1, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC10069558/#:~:text=In%20late%202020%2C%20Oregon%20became,legalize%20it%20for%20therapeutic%20use.
staff, Editorial. “The Power of Layered IP: Building a Robust Intellectual Property Strategy for the Modern Era - IP Business Academy.” IP Business Academy - Your global IP-Management Education Platform, February 17, 2025. https://ipbusinessacademy.org/the-power-of-layered-ip-building-a-robust-intellectual-property-strategy-for-the-modern-era.
Stringer, Heather. “The Emergence of Psychedelics as Medicine.” Monitor on psychology, June 1, 2024. https://www.apa.org/monitor/2024/06/psychedelics-as-medicine.
Understanding patent pledges: An overview of legal ... Accessed March 10, 2025. https://patentcommons.org/publications/OSDL_Whitepaper_Final_final_4-12-06.pdf.
Wolfgang, Aaron S., Gregory A. Fonzo, Joshua C. Gray, John H. Krystal, Adrienne Grzenda, Alik S. Widge, Nina V. Kraguljac, William M. McDonald, Carolyn I. Rodriguez, and Charles B. Nemeroff. “MDMA and MDMA-Assisted Therapy.” American Journal of Psychiatry 182, no. 1 (January 1, 2025): 79–103. https://doi.org/10.1176/appi.ajp.20230681.
“Tesla’s Open Source Revolution: Balancing Corporate Strategy and Public Good.” IP Law 422 001. Accessed April 11, 2025. https://iplaw.allard.ubc.ca/2024/12/21/teslas-open-source-revolution-balancing-corporate-strategy-and-public-good/#:~:text=Tesla%27s%20Open%20Source%20Patent%20Pledge&text=The%20pledge%20explicitly%20stated%20that,its%20patents%20in%20good%20faith.